Resverlogix Corp.

Industry:

Pharmaceuticals, Drug Manufacturing & Research, Biotechnology

Description

Resverlogix Corp. is a Canadian biotechnology company engaged in the discovery and development of pharmaceuticals. It has developed three separate programs in the cardiovascular disease (CVD) area of research. The primary CVD program is NexVas Plaque Regression (NexVas PR), which targets ApoA-I enhancement via small molecules for plaque stabilization and regression. ApoA-I is the key building block of lipoprotein (HDL), the good cholesterol. NexVas Vascular Inflammation (NexVas VI), its second CVD program, is a research stage technology focused on molecular targets of vascular inflammation. ReVas is its third cardiovascular program dedicated to the research and development of therapeutic compounds to be used with medical devices and biomaterials for the local non-systemic treatment of CVD, in particular restenosis. NexVas Alzheimer’s Disease is a discovery stage technology for the development of drugs that enhance ApoA-I for stabilization and regression of Beta Amyloid Plaque.
(Source: ARS)

View More Statistics

Site Statistics

Monthly Unique Visitors:	172
Site Rank:	3,434,236
Trust Rating:	Neutral
Stats by

News Archive

Resverlogix Notice of Conference Call & Webcast to Discuss Clinical Trial Data. PR Newswire Europe; 9/25/2009 ...Canada, September 25 /PRNewswire/ -- Resverlogix Corp. (TSX:RVX) announced today...will be posted onto the homepage of Resverlogix's website and can be accessed from...The webcast will be available on the Resverlogix website for replay for a period of 45... ...more

Resverlogix Phase 1b/2a Study Meets Primary Endpoint. Clinical Trials Week; 9/7/2009 Resverlogix Corp. (TSX:RVX) is pleased to announce...Congress meeting in Barcelona, Spain. Resverlogix will be attending this important cardiovascular...208 data on September 2, 2009 for Resverlogix during this meeting. Since RVX-208... ...more

Resverlogix Appoints A. Brad Cann as Chief Financial Officer. PR Newswire; 10/13/2009 ...CALGARY, Oct. 13 /PRNewswire-FirstCall/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces...investing, financial and partnering transactions. Resverlogix is a biotechnology company focused on delivering... ...more